Compare Johnson & Johnson (JNJ) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs NEOS S&P 500 High Income ETF — how do they compare? Johnson & Johnson trades at $260.85 (market cap $618.09B), while NEOS S&P 500 High Income ETF trades at $54.07 (market cap $12.50B). The key difference: Johnson & Johnson is far larger — about 49.4× NEOS S&P 500 High Income ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while NEOS S&P 500 High Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and NEOS S&P 500 High Income ETF for 57 Days on average.
| JNJ | SPYI | |
|---|---|---|
Market Cap | $618.09B | $12.50B |
Volume | 6,050,983 | 3,058,962 |
Sector | Health | Income / Options Overlay |
52-Week High | $278.43 | $54.42 |
52-Week Low | $186.00 | $47.98 |
Typical Hold Time | 129 Days | 57 Days |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
SPYI trades at $53.995, showing minimal daily movement with a slight 0.03% decline. The technical outlook is bullish based on moving averages, though oscillators remain neutral. Recent news highlights SPYI's role in income-focused portfolios, with coverage discussing both its high distribution yields and potential risks to principal value from covered call strategies.
The outlook for SPYI centers on its income generation appeal amid market volatility, but investors should weigh the trade-off between high yields and potential capital erosion. Key risks include sequence risk in retirement portfolios and the cap on upside during strong bull markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
